ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 102 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,927 | -33.5% | 5,071 | +19.4% | 0.00% | -50.0% |
| Q2 2023 | $40,464 | +14.8% | 4,246 | +32.5% | 0.00% | +100.0% |
| Q1 2023 | $35,244 | -32.6% | 3,204 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $52,289 | -14.3% | 3,204 | 0.0% | 0.00% | -33.3% |
| Q3 2022 | $61,000 | +10.9% | 3,204 | +22.0% | 0.00% | +50.0% |
| Q2 2022 | $55,000 | +52.8% | 2,627 | +39.7% | 0.00% | +100.0% |
| Q1 2022 | $36,000 | -7.7% | 1,880 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $39,000 | -13.3% | 1,880 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $45,000 | -11.8% | 1,880 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $51,000 | -5.6% | 1,880 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $54,000 | +25.6% | 1,880 | +22.1% | 0.00% | 0.0% |
| Q4 2020 | $43,000 | -4.4% | 1,540 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $45,000 | +66.7% | 1,540 | +71.7% | 0.00% | +100.0% |
| Q2 2020 | $27,000 | 0.0% | 897 | 0.0% | 0.00% | -50.0% |
| Q1 2020 | $27,000 | – | 897 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |